Product Code: IRTNTR6443
About Autoimmune Diseases
Autoimmune diseases are caused by aggravation of the immune system. Autoimmune diseases can last for months or even years. Autoimmune reactions occur when the immune system produces autoantibodies that attack and destroy healthy tissues in the body rather than infectious agents. These autoantibodies cause inflammation, pain, and organ damage. It is also known as a disease of flare-ups and remissions, and can range from mild to life-threatening in severity. No cure exists for autoimmune diseases yet. Autoimmune diseases can affect the cardiovascular system, brain, nerves, musculoskeletal system, skin, lungs, kidneys, glands, or joints. They are caused by genetic, infectious, and environmental factors. According to NIH, there are more than 80 clinically different autoimmune diseases. Some of the common types of autoimmune diseases are ankylosing spondylitis, Crohn's disease, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and psoriasis.
Technavio's analysts forecast the autoimmune diseases market in the US to grow at a CAGR of 6.17% over the period 2014-2019.
Covered in this Report
The report includes the present scenario and the growth prospects of the autoimmune diseases market in the US for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of autoimmune diseases.
Technavio's report, Autoimmune Diseases Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast for individual diseases as well as the overall market and pipeline landscape. The report includes a discussion of the key vendors operating in this market.
Key Vendors
- AbbVie
- Amgen
- Biogen
- F. Hoffmann-La Roche
- Janssen Pharmaceuticals
Other Prominent Vendors
- AB Science
- Acorda Therapeutics
- aTyr Pharma
- Baxter
- Celgene
- Celltrion
- Coherus BioSciences
- Daiichi Sankyo
- Eli Lilly
- GlaxoSmithKline
- HGS
- Hospira
- Idera
- Immunomedics
- ImmuPharma
- Invion
- Latona Life Sciences
- MedImmune
- Merck
- Novartis
- Opexa Therapeutics
- Principia
- Reata Pharmaceuticals
- Regeneron
- Sanofi
- Sobi
- Takeda
- Teva
- UCB
- Vaccinex
- Vitae Pharmaceuticals
Key Market Driver
- Unmet Medical Needs
- For a full, detailed list, view our report
Key Market Challenge
- High Cost of Therapy
- For a full, detailed list, view our report
Key Market Trend
- Increase in Public Awareness
- For a full, detailed list, view our report
Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Table of Contents
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
- 03.1. Market Overview
- 03.2. Product Offerings
04. Market Research Methodology
- 04.1. Market Research Process
- 04.2. Research Methodology
05. Introduction
06. Disease Overview
- 06.1. Understanding the Disease
- 06.2. Epidemiology
- 06.3. Etiology
- 06.4. Symptoms
- 06.5. Diagnosis
- 06.5.1. Medical History
- 06.5.2. Laboratory examination
- 06.6. Disease Management
- 06.7. Quality of Life
07. Market Landscape
- 07.1. Market Overview
- 07.2. Market Size and Forecast
08. Pipeline Portfolio
- 08.1. Pipeline Landscape: Crohn's Disease
- 08.2. Pipeline Landscape: Multiple Sclerosis
- 08.3. Pipeline Landscape: Systemic Lupus Erythematosus
- 08.5. Five Forces Analysis
09. Market Segmentation by Type of Diseases
- 09.1. Ankylosing Spondylitis
- 09.2. Crohn's Disease
- 09.3. Multiple Sclerosis
- 09.4. Psoriasis
- 09.5. Rheumatoid Arthritis
- 09.6. Systemic Lupus Erythematosus
10. Market Segmentation by Type of Molecules
- 10.1.1. Small Molecules
- 10.1.2. Biologics
11. Market Segmentation by Route of Administration
- 11.1.1. Parenteral Route
- 11.1.2. Oral Route
12. Ankylosing Spondylitis Market in the US
- 12.1. Market Size and Forecast
13. Crohn's Disease Market in the US
- 13.1. Market Size and Forecast
14. Multiple Sclerosis Market in the US
- 14.1. Market Size and Forecast
15. Rheumatoid Arthritis Market in the US
- 15.1. Market Size and Forecast
16. Psoriasis Market in the US
- 16.1. Market Size and Forecast
17. Systemic Lupus Erythematosus Market in the US
- 17.1. Market Size and Forecast
18. Buying Criteria
19. Market Growth Drivers
20. Drivers and their Impact
21. Market Challenges
22. Impact of Drivers and Challenges
23. Market Trends
24. Trends and their Impact
25. Vendor Landscape
- 25.1. Competitive Scenario
- 25.1.1. Key News
- 25.1.2. Mergers and Acquisitions
- 25.2. Market Share Analysis 2014
- 25.2.1. AbbVie
- 25.2.2. Janssen Pharmaceuticals
- 25.2.3. Biogen
- 25.2.4. Amgen
- 25.2.5. F. Hoffmann-La Roche
- 25.3. Other and Future Prominent Vendors
26. Key Vendor Analysis
- 26.1. AbbVie
- 26.1.1. Key Facts
- 26.1.2. Business Overview
- 26.1.3. Product Segmentation by Revenue 2013
- 26.1.4. Product Segmentation by Revenue 2012 and 2013
- 26.1.5. Sales by Geography
- 26.1.6. Business Strategy
- 26.1.7. Key Developments
- 26.1.8. SWOT Analysis
- 26.2. Amgen
- 26.2.1. Key Facts
- 26.2.2. Business Overview
- 26.2.3. Business Segmentation by Revenue 2013
- 26.2.4. Product Portfolio by Revenue 2013
- 26.2.5. Business Segmentation by Revenue 2012 and 2013
- 26.2.6. Geographical Segmentation by Revenue 2013
- 26.2.7. Business Strategy
- 26.2.8. Recent Developments
- 26.2.9. SWOT Analysis
- 26.3. Biogen
- 26.3.1. Key Facts
- 26.3.2. Business Overview
- 26.3.3. Business Segmentation by Revenue 2013
- 26.3.4. Geographical Segmentation by Revenue 2013
- 26.3.5. Business Strategy
- 26.3.6. Key Developments
- 26.3.7. SWOT Analysis
- 26.4. F. Hoffmann-La Roche
- 26.4.1. Key Facts
- 26.4.2. Business Overview
- 26.4.3. Business Segmentation
- 26.4.4. Business Segmentation by Revenue 2012 and 2013
- 26.4.5. Sales by Geography
- 26.4.6. Business Strategy
- 26.4.7. Key Information
- 26.4.8. SWOT Analysis
- 26.5. Janssen Pharmaceuticals
- 26.5.1. Key Facts
- 26.5.2. Business Overview
- 26.5.3. Recent Developments
- 26.5.4. SWOT Analysis
List of Exhibits
- Exhibit 1: Market Research Methodology
- Exhibit 2: Autoimmune Diseases Market in the US 2014-2019 (US$ million)
- Exhibit 3: Segmentation of Autoimmune Diseases Market in the US by Type of Diseases
- Exhibit 4: Percentage Share of Autoimmune Diseases Market Segment by Type of Disease 2014
- Exhibit 5: Segmentation of Autoimmune Diseases Market in the US by Type of Molecules
- Exhibit 6: Segmentation of Autoimmune Diseases Market in the US by Route of Administration
- Exhibit 7: Ankylosing Spondylitis Market in the US 2014-2019 ($ millions)
- Exhibit 8: Crohn's Disease Market in the US 2014-2019 ($ millions)
- Exhibit 9: Multiple Sclerosis Market in the US 2014-2019 ($ millions)
- Exhibit 10: Rheumatoid Arthritis Market in the US 2014-2019 ($ millions)
- Exhibit 11: Psoriasis Market in the US 2014-2019 ($ millions)
- Exhibit 12: Systemic Lupus Erythematosus Market in the US 2014-2019 ($ millions)
- Exhibit 13: Autoimmune Diseases Market in the US 2014-2019 ($ millions)
- Exhibit 14: AbbVie: Product Portfolio for Autoimmune Diseases
- Exhibit 15: YoY Revenue of Humira in the US 2009-2014 ($ millions)
- Exhibit 16: Janssen: Product Portfolio for Autoimmune Diseases
- Exhibit 17: YoY Global Revenue of Remicade 2009-2014 ($ millions)
- Exhibit 18: YoY Global Revenue of Simponi 2010-2014 ($ millions)
- Exhibit 19: Biogen: Product Portfolio for Autoimmune Diseases
- Exhibit 20: Biogen: Product Portfolio for Autoimmune Diseases
- Exhibit 21: YoY Revenue of Tysabri in the US 2009-2014 ($ millions)
- Exhibit 22: Revenue of Avonex in the US 2011-2014 ($ millions)
- Exhibit 23: Region-wise Revenues of Plegridy 2014 ($ millions)
- Exhibit 24: Region-wise Revenues of Tecfidera 2014 ($ millions)
- Exhibit 25: Amgen: Product Portfolio for Autoimmune Diseases
- Exhibit 26: Roche: Product Portfolio for Autoimmune Diseases
- Exhibit 27: AbbVie Inc.: Product Segmentation by Revenue 2013
- Exhibit 28: AbbVie Inc.: Product Segmentation by Revenue 2012 and 2013 (US$ million)
- Exhibit 29: AbbVie Inc.: Sales by Geography 2013
- Exhibit 30: Amgen: Business Segmentation by Revenue 2013
- Exhibit 31: Amgen: Product Portfolio by Revenue 2013
- Exhibit 32: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
- Exhibit 33: Amgen: Geographical Segmentation by Revenue 2013
- Exhibit 34: Biogen: Business Segmentation by Revenue 2013
- Exhibit 35: Biogen: Geographical Segmentation by Revenue 2013
- Exhibit 36: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
- Exhibit 37: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
- Exhibit 38: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
- Exhibit 39: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
